Search

Your search keyword '"Ingelmo-Torres, Mercedes"' showing total 169 results
Start Over Author "Ingelmo-Torres, Mercedes"
169 results on '"Ingelmo-Torres, Mercedes"'

3. Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy.

Author

Figueras, Marcel, Mengual, Lourdes, Ingelmo-Torres, Mercedes, Roldán, Fiorella L., Padullés, Bernat, Alfambra, Héctor, Herranz, Sandra, Paredes, Pilar, Amseian, Gary, Mases, Joel, Ribal, Maria J., Izquierdo, Laura, and Alcaraz, Antonio

Subjects
CELL-free DNA, PROSTATE-specific antigen, RADICAL prostatectomy, DISEASE relapse, PROGNOSIS, PROSTATE cancer
Abstract

Background/Objectives: Currently, the prediction of disease recurrence after radical prostatectomy (RP) in localized prostate cancer (PCa) relies on clinicopathological parameters, which lack accuracy in predicting clinical outcomes. This study focused on evaluating the utility of cfDNA levels and fragmentation patterns as prognostic biomarkers in progressive prostate-specific antigen (PSA) patients, including those with persistent PSA and biochemical recurrence (BR), after primary treatment in localized PCa patients. Methods: Twenty-nine high-risk localized PCa patients were enrolled in the study between February 2022 and May 2023. Blood samples were obtained before robotic RP. cfDNA concentration and fragment size were quantified using the Quant-it PicoGreen dsDNA Assay kit and Agilent 2200 TapeStation System, respectively. Results: The mean PSA value at diagnosis was 9.4 ng/mL. Seven patients (24.1%) had stage pT2 and 22 (75.9%) pT3. Nine patients (31%) had detectable PSA at the first PSA control six weeks after surgery, and four patients (20%) had BR during a mean follow-up of 18.4 months. No associations were found between cfDNA levels or fragmentation patterns and clinicopathological data. Although not statistically significant, patients with detectable PSA levels post-surgery exhibited higher cfDNA levels and shorter fragments compared with those with undetectable PSA. Conclusions: Our study indicated a tendency toward more fragmented cfDNA levels in PCa patients with persistent PSA. Strikingly, biochemical recurrent PCa patients exhibited similar cfDNA levels and fragmentation patterns compared to non-recurrent patients. Further studies exploring liquid biopsy-derived biomarkers in localized PCa patients are needed to elucidate their clinical utility in predicting PSA persistence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. MP15-05 PROGNOSTIC VALUE OF TUMOR-AGNOSTIC CIRCULATING TUMOR DNA TESTING IN MUSCLE-INVASIVE BLADDER CANCER

Author

Carrasco, Raquel, primary, Ingelmo-Torres, Mercedes, additional, Trullas, Ramón, additional, Roldán, Fiorella L., additional, Rodríguez-Carunchio, Leonardo, additional, Figueras, Marcel, additional, Mercader, Claudia, additional, Padullés, Bernat, additional, Olegario, Jasmine L., additional, Sureda, Joan, additional, Alcaraz, Antonio, additional, Izquierdo, Laura, additional, and Mengual, Lourdes, additional

Published
2024
Full Text
View/download PDF

5. MP41-17 CIRCULATING TUMOUR CELLS AND CELL-FREE DNA ANALYSIS FOR MONITORING DISEASE PROGRESSION IN LOCALIZED PROSTATE CANCER

Author

Figueras, Marcel, primary, Ingelmo-Torres, Mercedes, additional, Carrasco, Raquel, additional, Roldán, Fiorella L., additional, Padullés, Bernat, additional, Mercader, Claudia, additional, Gomez, Ascensión, additional, Pagés, Rita, additional, Alcaraz, Antonio, additional, Mengual, Lourdes, additional, and Izquierdo, Laura, additional

Published
2024
Full Text
View/download PDF

7. Prognostic Value of Liquid-Biopsy-Based Biomarkers in Upper Tract Urothelial Carcinoma

Author

Padullés, Bernat, primary, Carrasco, Raquel, additional, Ingelmo-Torres, Mercedes, additional, Roldán, Fiorella L., additional, Gómez, Ascensión, additional, Vélez, Elena, additional, Alfambra, Héctor, additional, Figueras, Marcel, additional, Carrion, Albert, additional, Gil-Vernet, Jordi, additional, Mengual, Lourdes, additional, Izquierdo, Laura, additional, and Alcaraz, Antonio, additional

Published
2024
Full Text
View/download PDF

11. LBA03-11 CLINICAL UTILITY OF SERIAL CELL-FREE DNA ANALYSIS FOR MONITORING MUSCLE-INVASIVE BLADDER CANCER PATIENTS

Author

Mengual, Lourdes, primary, Carrasco, Raquel, additional, Ingelmo-Torres, Mercedes, additional, Gómez, Ascensión, additional, Trullas, Ramón, additional, Roldán, Fiorella L., additional, Ajami, Tarek, additional, Sureda, Joan, additional, Herranz, Sandra, additional, Alcaraz, Antonio, additional, and Izquierdo, Laura, additional

Published
2023
Full Text
View/download PDF

12. Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer

Author

Instituto de Salud Carlos III, European Commission, Carrasco, Raquel [0000-0002-2792-5316], Trullas, Ramón [0000-0001-7951-9881], Mengual, Lourdes [0000-0001-7418-9422], Carrasco, Raquel, Ingelmo-Torres, Mercedes, Trullas, Ramón, Roldán, Fiorella L., Rodríguez-Carunchio, Leonardo, Juez, Lourdes, Sureda, Joan, Alcaraz, Antonio, Mengual, Lourdes, Izquierdo, Laura, Instituto de Salud Carlos III, European Commission, Carrasco, Raquel [0000-0002-2792-5316], Trullas, Ramón [0000-0001-7951-9881], Mengual, Lourdes [0000-0001-7418-9422], Carrasco, Raquel, Ingelmo-Torres, Mercedes, Trullas, Ramón, Roldán, Fiorella L., Rodríguez-Carunchio, Leonardo, Juez, Lourdes, Sureda, Joan, Alcaraz, Antonio, Mengual, Lourdes, and Izquierdo, Laura

Abstract

Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T and ATM c.1236-2A>T) were analyzed in the patients’ plasma samples by droplet digital PCR to determine their ctDNA status. During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and 4 and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p < 0.05). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in a clinical setting could improve disease management and patients’ outcomes.

Published
2023

14. Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.

Author

Carrasco, Raquel, Ingelmo-Torres, Mercedes, Oriola, Josep, Roldán, Fiorella L., Rodríguez-Carunchio, Leonardo, Herranz, Sandra, Mellado, Begoña, Alcaraz, Antonio, Izquierdo, Laura, and Mengual, Lourdes

Subjects
CELL-free DNA, SOMATIC mutation, GENETIC mutation, CANCER invasiveness, NUCLEOTIDE sequencing, BLADDER cancer
Abstract

Background and aims: The spatial and temporal genetic heterogeneity of bladder cancer (BC) makes challenging to find specific drivers of metastatic disease, thus preventing to determine those BC patients at high risk of tumor progression. Our aim was to identify DNA mutations providing aggressive behavior to bladder tumors and analyze them in patients' cell-free DNA (cfDNA) during their follow-up after radical cystectomy (RC) in order to monitor tumor evolution. Methods: Six BC patients who underwent RC and presented disease progression during their follow-up were included. Next-generation sequencing was used to determine somatic mutations in several primary tumor and metastatic specimens from each patient. Shared DNA mutations between primary bladder tumor and metastatic sites were identified in cfDNA samples through droplet digital PCR. Results: Besides BC genetic heterogeneity, specific mutations in at least one of these genes --TERT, ATM, RB1, and FGFR3-- were found in primary tumors and their metastases in all patients. These mutations were also identified in the patients' cfDNA at different follow-up time points. Additionally, the dynamic changes of these mutations in cfDNA allowed us to determine tumor evolution in response to treatment. Conclusion: The analysis of BC mutations associated with poor prognosis in plasma cfDNA could be a valuable tool to monitor tumor evolution, thus improving the clinical management of BC patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Urine cell-based DNA methylation classifier for monitoring bladder cancer

Author

van der Heijden, Antoine G., Mengual, Lourdes, Ingelmo-Torres, Mercedes, Lozano, Juan J., van Rijt-van de Westerlo, Cindy C. M., Baixauli, Montserrat, Geavlete, Bogdan, Moldoveanud, Cristian, Ene, Cosmin, Dinney, Colin P., Czerniak, Bogdan, Schalken, Jack A., Kiemeney, Lambertus A. L. M., Ribal, Maria J., Witjes, J. Alfred, and Alcaraz, Antonio

Published
2018
Full Text
View/download PDF

19. Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer

Author

Instituto de Salud Carlos III, European Commission, Agencia Estatal de Investigación (España), Ministerio de Ciencia, Innovación y Universidades (España), Carrasco, Raquel, Ingelmo-Torres, Mercedes, Gómez, Ascención, Trullas, Ramón, Roldán, Fiorella L., Ajami, Tarek, Moreno, Davinia, Rodríguez-Carunchio, Leonardo, Alcaraz, Antonio, Izquierdo, Laura, Mengual, Lourdes, Instituto de Salud Carlos III, European Commission, Agencia Estatal de Investigación (España), Ministerio de Ciencia, Innovación y Universidades (España), Carrasco, Raquel, Ingelmo-Torres, Mercedes, Gómez, Ascención, Trullas, Ramón, Roldán, Fiorella L., Ajami, Tarek, Moreno, Davinia, Rodríguez-Carunchio, Leonardo, Alcaraz, Antonio, Izquierdo, Laura, and Mengual, Lourdes

Abstract

Cell-free DNA (cfDNA) has recently emerged as a real-time biomarker for diagnosis, monitoring and prediction of therapy response in tumoral disease. Here, we evaluated cfDNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer (MIBC) patients at different follow-up time points. Blood samples from 37 MIBC patients who underwent radical cystectomy (RC) were collected at cystectomy and 1, 4, 12 and 24 months later. Plasma cfDNA amount and fragmentation patterns were determined. Four mutations were analyzed in cfDNA to detect circulating tumor DNA (ctDNA) during patient follow-up. During a median follow-up of 36 months, 46% of patients progressed; median time to progression was 10 months. cfDNA levels and ctDNA status four months after RC were identified as independent prognostic biomarkers of tumor progression (HR 5.290; p = 0.033) and cancer-specific survival (HR 4.199; p = 0.038), respectively. Furthermore, ctDNA clearance four months after RC was significantly associated with patients’ clinical outcomes. In conclusion, cfDNA levels and ctDNA status four months after RC have prognostic implications in MIBC patients. In addition, cfDNA monitoring is useful to predict patient outcomes after RC. cfDNA analysis in the clinical setting could greatly improve MIBC patient management.

Published
2022

21. Clinicopathological and Molecular Prognostic Classifier for Intermediate/High-Risk Clear Cell Renal Cell Carcinoma

Author

Roldán, Fiorella L., primary, Lozano, Juan J., additional, Ingelmo-Torres, Mercedes, additional, Carrasco, Raquel, additional, Díaz, Esther, additional, Ramirez-Backhaus, Miguel, additional, Rubio, José, additional, Reig, Oscar, additional, Alcaraz, Antonio, additional, Mengual, Lourdes, additional, and Izquierdo, Laura, additional

Published
2021
Full Text
View/download PDF

22. A prospective validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring

Author

Mengual, Lourdes, primary, Frantzi, Maria, additional, Mokou, Marika, additional, Ingelmo-Torres, Mercedes, additional, Vlaming, Michiel, additional, Merseburger, Axel S., additional, Roesch, Marie C., additional, Culig, Zoran, additional, Alcaraz, Antonio, additional, Vlahou, Antonia, additional, Mischak, Harald, additional, and Van der Heijden, Antoine G., additional

Published
2021
Full Text
View/download PDF

33. Additional file 8: of Urine cell-based DNA methylation classifier for monitoring bladder cancer

Author

Heijden, Antoine Van Der, Mengual, Lourdes, Ingelmo-Torres, Mercedes, Lozano, Juan, Westerlo, Cindy Van Rijt-Van De, Baixauli, Montserrat, Geavlete, Bogdan, Moldoveanud, Cristian, Ene, Cosmin, Dinney, Colin, Czerniak, Bogdan, Schalken, Jack, Kiemeney, Lambertus, Ribal, Maria, J. Witjes, and Alcaraz, Antonio

Abstract

Figure S5. Flow diagram of participants in the cross-sectional study according a) to the three-gene methylation classifier and cytology results and b) to the combined three-gene methylation/cytology classifier. Abbreviations: R-PFBC, recurrent patients in follow-up for bladder cancer; NR-PFBC, non-recurrent patients in follow-up for bladder cancer; Cytol, cytology; NA, non-available; Test, combined three-gene methylation/cytology classifier. (PPTX 85Â kb)

Published
2018
Full Text
View/download PDF

34. Additional file 3: of Urine cell-based DNA methylation classifier for monitoring bladder cancer

Author

Heijden, Antoine Van Der, Mengual, Lourdes, Ingelmo-Torres, Mercedes, Lozano, Juan, Westerlo, Cindy Van Rijt-Van De, Baixauli, Montserrat, Geavlete, Bogdan, Moldoveanud, Cristian, Ene, Cosmin, Dinney, Colin, Czerniak, Bogdan, Schalken, Jack, Kiemeney, Lambertus, Ribal, Maria, J. Witjes, and Alcaraz, Antonio

Abstract

Figure S2. Pearson correlation coefficient heat map of the percentage of methylation for every CpG dinucleotide in the seven genes. Every CpG sites are correlated (via the Pearson correlation) with all others. Correlations are scaled by the color of the corresponding cell. Parameters are represented in the same order on the x- and y-axes. (PPTX 1232Â kb)

Published
2018
Full Text
View/download PDF

35. Additional file 7: of Urine cell-based DNA methylation classifier for monitoring bladder cancer

Author

Heijden, Antoine Van Der, Mengual, Lourdes, Ingelmo-Torres, Mercedes, Lozano, Juan, Westerlo, Cindy Van Rijt-Van De, Baixauli, Montserrat, Geavlete, Bogdan, Moldoveanud, Cristian, Ene, Cosmin, Dinney, Colin, Czerniak, Bogdan, Schalken, Jack, Kiemeney, Lambertus, Ribal, Maria, J. Witjes, and Alcaraz, Antonio

Abstract

Figure S4. Sensitivity, negative and positive predictive values of urine cytology, the three-gene methylation classifier, and the combined three-gene methylation/cytology classifier in the testing set (Nâ =â 308). Overall specificity was 94% for urine cytology, 27% for the three-gene methylation classifier, and 40% for the combined three-gene methylation/cytology classifier. Abbreviations: LG, low-grade; HG, high-grade; NMIBC nHR, non-muscle-invasive bladder cancer non-high risk; NMIBC HR, non-muscle-invasive bladder cancer high risk; NPV, negative predictive value; PPV, positive predictive value. (PPTX 189Â kb)

Published
2018
Full Text
View/download PDF

36. Additional file 5: of Urine cell-based DNA methylation classifier for monitoring bladder cancer

Author

Heijden, Antoine Van Der, Mengual, Lourdes, Ingelmo-Torres, Mercedes, Lozano, Juan, Westerlo, Cindy Van Rijt-Van De, Baixauli, Montserrat, Geavlete, Bogdan, Moldoveanud, Cristian, Ene, Cosmin, Dinney, Colin, Czerniak, Bogdan, Schalken, Jack, Kiemeney, Lambertus, Ribal, Maria, J. Witjes, and Alcaraz, Antonio

Abstract

Table S2. Percentage of methylation for each CpG dinucleotide in the seven selected genes in control and bladder cancer urine samples. Underlined in grey the CpG site used for methylation analysis. Abbreviations: SDV; Standard Deviation. (DOCX 21Â kb)

Published
2018
Full Text
View/download PDF

37. Additional file 6: of Urine cell-based DNA methylation classifier for monitoring bladder cancer

Author

Heijden, Antoine Van Der, Mengual, Lourdes, Ingelmo-Torres, Mercedes, Lozano, Juan, Westerlo, Cindy Van Rijt-Van De, Baixauli, Montserrat, Geavlete, Bogdan, Moldoveanud, Cristian, Ene, Cosmin, Dinney, Colin, Czerniak, Bogdan, Schalken, Jack, Kiemeney, Lambertus, Ribal, Maria, J. Witjes, and Alcaraz, Antonio

Abstract

Table S3. Diagnostic performance of the three-gene methylation classifier, cytology, and the combined methylation/cytology classifier in the training and testing subset of samples with cytology available. Abbreviations: LG, Low Grade; HG, High Grade; AUC, area under curve; MIBC, muscle invasive bladder cancer; NMIBC, Non-Muscle Invasive Bladder Cancer; NPV, Negative Predictive Value; PPV, Positive Predictive Value; SN, Sensitivity; SP, Specificity; BC, Bladder Cancer; C, Control; R-PFBC, Recurrent Patients in Follow up for Bladder Cancer; NR-PFBC, Non Recurrent Patients in Follow up for Bladder Cancer. (DOCX 20Â kb)

Published
2018
Full Text
View/download PDF

38. Additional file 2: of Urine cell-based DNA methylation classifier for monitoring bladder cancer

Author

Heijden, Antoine Van Der, Mengual, Lourdes, Ingelmo-Torres, Mercedes, Lozano, Juan, Westerlo, Cindy Van Rijt-Van De, Baixauli, Montserrat, Geavlete, Bogdan, Moldoveanud, Cristian, Ene, Cosmin, Dinney, Colin, Czerniak, Bogdan, Schalken, Jack, Kiemeney, Lambertus, Ribal, Maria, J. Witjes, and Alcaraz, Antonio

Abstract

Table S1. Primer sequences used in PCR and pyrosequencing. (DOCX 13Â kb)

Published
2018
Full Text
View/download PDF

39. Additional file 9: of Urine cell-based DNA methylation classifier for monitoring bladder cancer

Author

Heijden, Antoine Van Der, Mengual, Lourdes, Ingelmo-Torres, Mercedes, Lozano, Juan, Westerlo, Cindy Van Rijt-Van De, Baixauli, Montserrat, Geavlete, Bogdan, Moldoveanud, Cristian, Ene, Cosmin, Dinney, Colin, Czerniak, Bogdan, Schalken, Jack, Kiemeney, Lambertus, Ribal, Maria, J. Witjes, and Alcaraz, Antonio

Subjects
fungi
Abstract

Figure S6. DNA methylation profiles for bladder cancer and control tissue samples for the three-gene classifier. Data obtained from Wanderer Web page: http://maplab.imppc.org/wanderer/ . The red arrow indicates the CpG dinucleotide analyzed in each of the three genes. (PPTX 203Â kb)

Published
2018
Full Text
View/download PDF

40. Additional file 4: of Urine cell-based DNA methylation classifier for monitoring bladder cancer

Author

Heijden, Antoine Van Der, Mengual, Lourdes, Ingelmo-Torres, Mercedes, Lozano, Juan, Westerlo, Cindy Van Rijt-Van De, Baixauli, Montserrat, Geavlete, Bogdan, Moldoveanud, Cristian, Ene, Cosmin, Dinney, Colin, Czerniak, Bogdan, Schalken, Jack, Kiemeney, Lambertus, Ribal, Maria, J. Witjes, and Alcaraz, Antonio

Abstract

Figure S3. Representative pyrograms showing gene methylation patterns in DNA urine samples from a bladder cancer patient. Percentage of methylation is indicated above peaks (gray columns) corresponding to the CpG sites in this region. (PPTX 183Â kb)

Published
2018
Full Text
View/download PDF

41. MP63-14 EIGHT GENE EXPRESSION CLASSIFIER FOR NON INVASIVE BLADDER CANCER SURVEILLANCE

Author

Montalbo*, Ruth, primary, Lozano, Juan Jose, additional, Izquierdo, Laura, additional, Ingelmo-Torres, Mercedes, additional, Oria, Maria Pilar, additional, Palou, Juan, additional, van der Heijden, Antoine G., additional, Medina, Rafael, additional, Schmidbauer, Joerg, additional, Prat, Aleix, additional, Ribal, Maria J., additional, Alcaraz, Antonio, additional, and Mengual, Lourdes, additional

Published
2019
Full Text
View/download PDF

45. Additional file 1: Table S1. of Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers

Author

Mengual, Lourdes, Lozano, Juan, Ingelmo-Torres, Mercedes, Izquierdo, Laura, Musquera, Mireia, MarĂ­A Ribal, and Alcaraz, Antonio

Abstract

Commercial Gene Expression Assays from Life Technologies used in this study. Target exons for transcript detection as well as amplicon length for each trasncrip are shown. (DOCX 18 kb)

Published
2016
Full Text
View/download PDF

47. Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study

Author

Izquierdo, Laura, primary, Montalbo, Ruth, additional, Ingelmo-Torres, Mercedes, additional, Mallofré, Carme, additional, Ramírez-Backhaus, Miguel, additional, Rubio, Jose, additional, Van der Heijden, Antoine G., additional, Schaafsma, Ewout, additional, Lopez-Beltran, Antonio, additional, Blanca, Ana, additional, Lawrentschuk, Nathan, additional, Alcaraz, Antonio, additional, and Mengual, Lourdes, additional

Published
2017
Full Text
View/download PDF

49. Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma

Author

Izquierdo Reyes, Laura, Ingelmo-Torres, Mercedes, Mallofré i Gómez, Carme, Lozano Salvatella, Juan José, Verhasselt-Crinquette, Marie, LeRoy, Xavier, Colin, Pierre, Comperat, Eva, Roupret, Morgan, Alcaraz Asensio, Antonio, Mengual Brichs, Lourdes, and Universitat de Barcelona

Subjects
Micro RNAs, MicroRNAs, Reacció en cadena de la polimerasa, Càncer, Malalties de l'aparell urinari, Diseases of the urinary organs, Cancer, Polymerase chain reaction
Abstract

OBJECTIVE: To examine the microRNA (miRNA) expression pattern in tumour samples from patients with progressing and non-progressing upper tract urothelial carcinoma (UTUC) in order to identify putative miRNAs that may be used as prognostic markers. PATIENTS AND METHODS: We conducted a multicentre, retrospective study of formalin-fixed paraffin-embedded tissue samples from 150 patients with UTUC who had undergone radical nephroureterectomy. Global miRNA expression patterns were analysed in 18 selected samples from patients with UTUC using TaqMan arrays. The differential expression of five key miRNAs was validated by quantitative polymerase chain reaction in an independent cohort of 132 samples from patients with UTUC. Models to predict tumour progression and cancer-specific survival that included miRNA expression patterns were developed by Cox regression analysis. RESULTS: Twenty-six miRNAs were found to be aberrantly expressed between samples from patients with progressing and non-progressing UTUC and five of these were selected for subsequent studies. The regression analysis identified tumour stage and miR-31 and miR-149 expression as independently associated with tumour progression and tumour stage and miR-149 expression as independently associated with cancer-specific survival. The risk scores derived from these miRNA models were able to discriminate two groups with a highly significantly different probability of tumour progression (hazard ratio [HR] 4.78; P < 0.001) and death (HR 276; P = 0.004). CONCLUSIONS: There is a differential miRNA expression pattern between patients with progressing and non-progressing UTUC. The identification of new miRNAs associated with a high probability of tumour recurrence and cancer-specific survival in patients with UTUC and their combination in a robust, easy-to-use and reliable algorithm may help tailor treatment and surveillance strategies in these patients.

Published
2014

50. S&T-65 PROSPECTIVE, BLINDED, INTERNATIONAL AND MULTICENTER VALIDATION OF A GENE EXPRESSION TEST FOR THE NON-INVASIVE DIAGNOSIS OF BLADDER CANCER

Author

Mengual, Lourdes, primary, Ribal, Maria J., additional, Lozano, Juan J., additional, Ingelmo-Torres, Mercedes, additional, Liang, Jill, additional, Han, CT., additional, Palou, Juan, additional, Rodriguez-Faba, Oscar, additional, Witjes, Fred, additional, Van der Heijden, Antoine G., additional, Medina, Rafael, additional, Conde, JM., additional, Marberger, Michael, additional, Schmidbauer, Joerg, additional, Ye, Dingwei, additional, Ye, Xun, additional, Meng, Xia, additional, and Alcaraz, Antonio, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results